Telomeres and telomerase as targeted therapies in cancer treatment;Télomères et télomérase comme cibles thérapeutiques dans le traitement du cancer

Bulletin du Cancer

Volumn 97, Issue 9, 2010, Pages 1087-1104

  Souiden, Y ^a   Bouraoui, A ^b   Chaieb, K ^a   Mahdouani, K ^a  

^a Centre Hospitalo Universitaire Ibn El Jazzar De Kairouan   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

G quadruplex; Telomerase; Telomerase targeted cancer therapy; Telomere

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; FLUCYTOSINE; GANCICLOVIR; GUANINE QUADRUPLEX; RIBOZYME; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; ENZYME INHIBITOR; GRN163L PEPTIDE; LONG UNTRANSLATED RNA; OLIGONUCLEOTIDE; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE RNA; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; TERT PROTEIN, HUMAN; TUMOR PROTEIN; UNTRANSLATED RNA;

CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; ENZYME REGULATION; GENETIC TRANSCRIPTION; POSTTRANSCRIPTIONAL GENE SILENCING; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; TELOMERE; ANTAGONISTS AND INHIBITORS; CELL AGING; CELL DIVISION; CHEMISTRY; ENZYMOLOGY; FORECASTING; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; RNA PROCESSING;

CELL AGING; CELL DIVISION; ENZYME INHIBITORS; FORECASTING; G-QUADRUPLEXES; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE INHIBITORS; RNA; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, CATALYTIC; RNA, LONG NONCODING; RNA, UNTRANSLATED; TELOMERASE; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 1; TELOMERIC REPEAT BINDING PROTEIN 2; TRANSCRIPTION, GENETIC;

EID: 77957294490     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1155     Document Type: Review

References (81)

1. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline activity and embryonic tissues and cells. Dev Genet 1996 ; 18 : 173-9. (Pubitemid 26116862)
2. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci USA 1997 ; 94 : 10827-32.
3. Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, et al. Telomerase activity in normal human epithelial cells. Oncogene 1996 ; 13 : 433-9.
4. Riou JF, Morjani H, Trentesaux C. Télomères et télomérase, de nouvelles cibles pour la chimiothérapie anticancéreuse. Ann Pharm Fr 2006 ; 64 : 97-105.
5. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Mol Cell Biol 2000 ; 1 : 72-6.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
7. Dunham MA, Neuman NAA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000 ; 26 : 447-50.
8. Riou JF, Gomez D, Mergny JL, Guittat L, Paterski R, Chenais B, et al. Régulation de la longueur des télomères : rendre le télomère accessible ? Bull Cancer 2005 ; 92 : 13-22.
9. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Gene Dev 2005 ; 19 : 2100-10.
10. Kelleher C, Kurth I, Lingner J. Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro. Mol Cell Biol 2005 ; 25 : 808-18.
11. Ye JZ, Hockemeyer D, Krutchinsky AN, Loayza D, Hooper SM, Chait BT, et al. POT 1-interacting protein PIP1: a telomere length regulator that recruits POP1 to the TIN2/TRF1 complex. Genes Dev 2004 ; 18 : 1649-54.
12. Cook BD, Dynek JN, Chang W, Shostak G, Smith S. Role for the related poly(ADP-ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol 2002 ; 22 : 332-42.
13. Zhu XD, Kuster B, Mann M, Petrini JH, de Lange T. Cell cycleregulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet 2000 ; 25 : 347-52.
14. Opresko PL, von Kobbe C, Laine JP, Harrigan J, Hickson ID, Bohr VA. Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases. J Biol Chem 2002 ; 277 : 41110-9.
15. Song K, Jung D, Jung Y, Lee SG, Lee I. Interaction of human ku70 with TRF2. BEBS Lett 2000 ; 481 : 81-5.
16. Karlseder J, Hoke K, Mirzoeva OK, Bakkenist C, Kaston MB, Petrini JH, et al. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PloS Biol 2004 ; 2 : E240.
17. Gilson E. Une bonne année pour la télomérase. Bull Cancer 1998 ; 85 : 119-23.
18. Cohen SB, Graham ME, Lovreczy GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalitycally active human telomerase from immortal cells. Science 2007 ; 315 : 1850-3.
19. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol R 2002 ; 66 : 407-25.
20. Hoare SF, Bryce LA, Wisman GBA, Burns S, Going JJ, van de Zee AGJ, et al. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res 2001 ; 61 : 27-32.
21. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 2005 ; 65 : 7585-90.
22. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTα splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000 ; 2 : 426-32. (Pubitemid 32044788)
23. Lundblad V. Telomeres: taking the measure. Nature 2003 ; 423 : 926-7.
24. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005 ; 579 : 859-62.
25. Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, Soria JC. Telomeres and telomerase as targets for anticancer drug development. Crit Rev Oncol Hemat 2006 ; 57 : 191-214. (Pubitemid 43238325)
26. Ouellette MM, Lee K. Telomerase: diagnostics, cancer therapeutics and tissue engineering. Ther Focus 2001 ; 23 : 1231-7.
27. Folini M, Zaffaroni N. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies. Curr Pharm Design 2005 ; 11 : 1105-17.
28. Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 2005 ; 41 : 624-34.
29. Fuessel S, Meye A, Kraemer K, Kunze D, Hakenberg OW, Wirth MP. Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma. Eur Urol 2007 ; 51 : 315-27. (Pubitemid 44940905)
30. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003 ; 63 : 3931-9.
31. Gellert GC, Jackson SR, Dikmen ZG, Wright WE, Shay JW. Telomerase as therapeutic target in cancer. Drug Discovery Today Dis Mech 2005 ; 2 : 159-64.
32. Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR. Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res 2001 ; 29 : 1683-9.
33. Koga S, Kondo Y, Komata T, Kondo S. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther 2001 ; 8 : 654-8. (Pubitemid 32422061)
34. Kondo Y, Komata T, Kondo S. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol 2001 ; 18 : 1287-92.
35. Kore AR, Vaish NK, Kutzke U, Eckstein F. Sequence specificity of the hammerhead revisited: the NHH rule. Nucleic Acids Res 1998 ; 26 : 4116-20.
36. Yeo M, Rha Y, Jeung HC, Hu SX, Yang SH, Kim YS, et al. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int J Cancer 2005 ; 114 : 484-9.
37. Kanazawa Y, Ohkawa K, Ueda K, Mita E, Takehara T, Sasaki Y, et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophy Res Co 1996 ; 225 : 570-6.
38. Folini M, Pennati M, Zaffaroni N. Targeting human telomerase by antisense oligonucleotides and ribozymes. Curr Med Chem Anti-Cancer Agents 2002 ; 2 : 605-12.
39. Yokoyama Y, Takahashi Y, Shinohara A, Wan X, Takahashi S, Niwa K, et al. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem Biophy Res Co 2000 ; 273 : 316-21. (Pubitemid 30426904)
40. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002 ; 26 : 199-213.
41. Kosciolek BA, Kalantidis K, Tabler M, Rowley PT. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2003 ; 2 : 209-16.
42. Lu XD, Qin WX, Pan DN, Li JJ, Wan DF, Wen CJ, et al. A DNA vector-based RNAi technology to inhibit the activity of the telomerase of cell line HCCLM3. Zhonghua Yi Xue Za Zhi 2004 ; 84 : 1381-5.
43. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999 ; 5 : 1164-70.
44. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003 ; 113 : 881-9.
45. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000 ; 20 : 3764-71.
46. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999 ; 21 : 220-4. (Pubitemid 29070372)
47. Grand CL, Han H, Munoz RM, Weitman S, Von Hoff DD, Hurley LH, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002 ; 1 : 565-73.
48. Li H, Lee TH, Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-MYC-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 2002 ; 277 : 20965-73.
49. Goueli BS, Janknecht R. Upregulation of the catalytic telomerase subunit by the transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 2004 ; 24 : 25-35.
50. Guilleret I, Benhattar J. Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem Biophys Res Commun 2004 ; 325 : 1037-43. (Pubitemid 39487975)
51. Kitagawa Y, Kyo S, Takakura M, Kanaya T, Koshida K, Namiki M, et al. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res 2000 ; 6 : 2868-75.
52. Woo HJ, Lee SJ, Choi BT, Park YM, Choi YH. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937cells. Exp Mol Pathol 2007 ; 82 : 77-84.
53. Wang Z, Kyo S, Takakura M, Tanaka M, Yatabe N, Maida Y, et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res 2000 ; 60 : 5376-81.
54. Kimura A, Ohmichi M, Kawagoe J, Kyo S, Mabuchi S, Takahashi T, et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004 ; 23 : 4505-15.
55. Yu CC, Lo SC, Wang TC. Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells. Biochem J 2001 ; 355 : 459-64.
56. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001 ; 107 : 67-77.
57. Riou JF, Gomez D, Lemarteleur T, Trentesaux C. L'ADN Gquadruplexe : mythe ou réalité ? Bull Cancer 2003 ; 90 : 305-13.
58. Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, et al. G-quadruplex as targets for drug design. Pharmacol Ther 2000 ; 85 : 141-58.
59. Gowan SM, Harrison JR, Patterson L, Valenti M, Read M, Neidle S, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002 ; 61 : 1154-62. (Pubitemid 34441781)
60. Shin-Y AK, Wierzba K, Matsuo K, Ohtani T, Yamada Y, Furihata K, et al. Telomestatin, a novel telomerase inhibitor from streptomyces anulatus. J Am Chem Soc 2001 ; 123 : 1262-3.
61. Gomez D, Paterski R, Lemarteleur T, Shin-ya K, Mergny JL, Riou JF. Interaction of telomestatin with the telomeric single-strand overhang. J Biol Chem 2004 ; 279 : 41487-94.
62. Gomez D, Wenner T, Brassard B, Douarre C, O'Donohue MF, ElKhoury V, et al. Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extention in HT1080 human tumor cells. J Biol Chem 2006 ; 281 : 38721-9.
63. de Cian A, Lacroix L, Douarre C, Temime-Smaali N, Trentesaux C, Riou JF, et al. Targeting telomeres and telomerase. Biochimie 2008 ; 90 : 131-55.
64. Huppert JL, Balasubramanian S. G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res 2007 ; 35 : 406-13. (Pubitemid 46232058)
65. Karlseder J, Broccoli D, Dai Y, Hardy S, De Lange T. p53- and ATM dependent apoptosis induced by telomeres lacking TRF2. Science 1999 ; 283 : 1321-5.
66. Ancelin K, Brunori M, Bauwens S, Koering CE, Brun C, Ricoul M, et al. Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol 2002 ; 22 : 3474-87.
67. Seimiya H. The telomeric PARP, tankyrase, as targets for cancer therapy. Br J Cancer 2006 ; 94 : 341-5. (Pubitemid 43237557)
68. Melana SM, Holland JF, Pogo BG. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′- azido-3′- deoxythymidine. Clin Cancer Res 1998 ; 4 : 693-6.
69. El-Daly H, Kull M, Zimmermann S, Waller CF, Matens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005 ; 105 : 1742-9.
70. Cortez-Gonzalez X, Zanetti M. Telomerase immunity from bench to beside: round one. J Transl Med 2007 ; 5 : 12.
71. Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004 ; 11 : 174-85.
72. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004 ; 10 : 285-92.
73. Yeh YM, Pan YT, Wang TC. Cdc42/Rac1 participates in the control of telomerase activity in human nasopharyngeal cancer cells. Cancer Lett 2005 ; 218 : 207-13.
74. Keppler BR, Jarstfer MB. Inhibition of telomerase activity by preventing proper assemblage. Cancer Gene Ther 2004 ; 43 : 334-43.
75. He H, Xia HHX, DeWang J, Gu Q, Lin MCM, Zou B, et al. Inhibition of human telomerase reverse transcriptase by nonsteroidal anti-inflammatory drugs in colon carcinoma. Cancer 2006 ; 106 : 1243-9.
76. Bermudez Y, Ahmadi S, Lowell NE, Kruk PA. Vitamin E suppresses telomerase activity in ovarian cancer cells. Cancer Detect Prev 2007 ; 31 : 119-28. (Pubitemid 46669813)
77. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004 ; 279 : 53213-21.
78. Elmore LW, Holt SE. Telomerase inhibition as an adjuvant anticancer therapy: it is more than just a waiting game. Expert Opin Ther Targets 2007 ; 11 : 427-30.
79. Boukamp P, Mirancea N. Telomeres rather than telomerase a key target for anticancer therapy? Exp Dermatol 2007 ; 16 : 71-9.
80. Burger AM. Highlights in experimental therapeutics. Cancer Lett 2007 ; 245 : 11-21.
81. Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007 ; 11 : 461-9.